Pharmaceutical Technology6d
Pegtarazimod by ReAlta Life Sciences for Coronavirus Disease 2019 (COVID-19) Associated Acute Lung Injury: Likelihood of Approval
Pegtarazimod is under clinical development by ReAlta Life Sciences and currently in Phase I for Coronavirus Disease 2019 (COVID-19) Associated Acute Lung Injury.
Frontiers18d
Gut microbiota in post-acute COVID-19 syndrome: not the end of the story
Tianjin Key Laboratory of Digestive Diseases, Department of Gastroenterology and Hepatology, Tianjin Institute of Digestive Diseases, National Key Clinical Specialty, General Hospital, Tianjin Medical ...